Evidence map›Paper›PMID 40303499›Full record

ArticleInternational journal of medical sciences2025

Malignant features related PRDX1 associated with osimertinib sensitivity of EGFR-mutant lung adenocarcinoma.

Wenying Jiang, Maonan Wang, Xiaoqian Yu, Guoqian Liu, Xiaoyun He, Cheng Mei, Chunlin Ou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenying JiangDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Maonan WangDepartment of Pathology, Xiangya Hospital, School of Basic Medical Sciences, Central South University, Changsha 410000, Hunan, China.
Xiaoqian YuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Guoqian LiuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Xiaoyun HeDepartments of Ultrasound Imaging, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Cheng MeiDepartment of Blood Transfusion, Xiangya Hospital, Clinical Transfusion Research Center, Central South University, Changsha 410008, Hunan, China.
Chunlin OuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The peroxiredoxin (PRDX) family, also known as the peroxidase family, consists of six members that participate in a variety of essential bio-processes in carcinogenesis. However, their molecular role in lung adenocarcinoma (LUAD) has not been systematically explored. Using bioinformatic tools, we systematically analyzed the expression, prognostic value and drug sensitivity of the PRDX gene family members in LUAD. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to verify the expression of PRDX1 in both LUAD tissues and cells. Cell Counting Kit-8 (CCK-8) assay was applied to detect the half-maximal inhibitory concentration (IC

Indexed as

AcrylamidesAdenocarcinoma of LungAniline CompoundsLung NeoplasmsPeroxiredoxinsAnimalsApoptosisBiomarkers, TumorCell Line, TumorCell ProliferationDrug Resistance, NeoplasmErbB ReceptorsFemaleGene Expression Regulation, NeoplasticHumansIndolesAcrylamidesAniline CompoundsBiomarkers, TumorEGFR protein, humanErbB ReceptorsIndolesosimertinibPeroxiredoxinsPRDX1 protein, humanProtein Kinase InhibitorsPyrimidinesimmune infiltrationimmunotherapylung adenocarcinomaPRDX familyprognosistherapeutic target

Identifiers

PMID40303499
PMCPMC12035832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.